JP2017535601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535601A5 JP2017535601A5 JP2017543329A JP2017543329A JP2017535601A5 JP 2017535601 A5 JP2017535601 A5 JP 2017535601A5 JP 2017543329 A JP2017543329 A JP 2017543329A JP 2017543329 A JP2017543329 A JP 2017543329A JP 2017535601 A5 JP2017535601 A5 JP 2017535601A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- apilimod
- therapeutic
- renal
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077127P | 2014-11-07 | 2014-11-07 | |
| US62/077,127 | 2014-11-07 | ||
| PCT/US2015/059512 WO2016073877A1 (en) | 2014-11-07 | 2015-11-06 | Apilimod for use in the treatment of renal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535601A JP2017535601A (ja) | 2017-11-30 |
| JP2017535601A5 true JP2017535601A5 (enExample) | 2018-12-13 |
| JP6705828B2 JP6705828B2 (ja) | 2020-06-03 |
Family
ID=54548302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543329A Expired - Fee Related JP6705828B2 (ja) | 2014-11-07 | 2015-11-06 | 腎癌の処置に使用するためのアピリモド |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10206910B2 (enExample) |
| EP (2) | EP3581184B1 (enExample) |
| JP (1) | JP6705828B2 (enExample) |
| KR (1) | KR20170098812A (enExample) |
| CN (1) | CN107249638B (enExample) |
| AU (1) | AU2015342869A1 (enExample) |
| BR (1) | BR112017008799A2 (enExample) |
| CA (1) | CA2966359A1 (enExample) |
| ES (1) | ES2741399T3 (enExample) |
| HU (1) | HUE044557T2 (enExample) |
| IL (1) | IL251905B (enExample) |
| MX (1) | MX377593B (enExample) |
| PL (1) | PL3215158T3 (enExample) |
| PT (1) | PT3215158T (enExample) |
| RU (1) | RU2727802C2 (enExample) |
| WO (1) | WO2016073877A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6855243B2 (ja) | 2014-01-24 | 2021-04-07 | エイアイ・セラピューティクス・インコーポレーテッド | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| HUE044557T2 (hu) | 2014-11-07 | 2019-11-28 | Ai Therapeutics Inc | Apilimod, veserák kezelésében történõ alkalmazásra |
| RU2739992C2 (ru) * | 2014-11-07 | 2020-12-30 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Композиции апилимода и способы их применения в лечении колоректального рака |
| RU2018130070A (ru) * | 2016-01-21 | 2020-02-21 | Лэм Терапьютикс, Инк. | Биомаркеры для лечения рака при помощи апилимода |
| CA3034453A1 (en) * | 2016-08-25 | 2018-03-01 | AI Therapeutics, Inc. | Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling |
| CA3039199A1 (en) * | 2016-10-12 | 2018-04-19 | AI Therapeutics, Inc. | Apilimod compositions and methods for using same in the treatment of alzheimer's disease |
| CA3056909A1 (en) | 2017-03-24 | 2018-09-27 | Nanosyn, Inc. | Fused triazolo-pyrimidine compounds having useful pharmaceutical application |
| IL276158B2 (en) | 2018-01-26 | 2024-07-01 | Univ California | Methods and preparations for the treatment of angiogenic disorders using anti-VEGF factors |
| AU2019223014B2 (en) | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| CA3167339A1 (en) | 2020-01-13 | 2021-07-22 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| CN114306370A (zh) * | 2021-12-31 | 2022-04-12 | 北京悦康科创医药科技股份有限公司 | 反义寡核苷酸在制备治疗肾癌药物中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| DK1921169T3 (da) | 1993-11-12 | 2012-06-04 | Phri Properties Inc | Hybridiseringssonder til nukleinsyredetektion, universelle stamceller, fremgangsmåder og kits |
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| EA009873B1 (ru) | 2004-02-06 | 2008-04-28 | Элан Фармасьютикалз, Инк. | Способ ингибирования роста опухоли и/или метастатического прогрессирования |
| EP1737845A4 (en) | 2004-04-13 | 2010-07-21 | Synta Pharmaceuticals Corp | DISPLAY HEMMER OF IL-12 PRODUCTION |
| WO2006029385A2 (en) | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds. |
| WO2006053112A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Process for preparing trisubstituted pyrimidine compounds |
| US7863270B2 (en) | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006128129A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| EP2385053B1 (en) | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| JP5156644B2 (ja) | 2006-01-25 | 2013-03-06 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | 不飽和ｍＴＯＲ阻害剤 |
| JP5215300B2 (ja) | 2006-07-12 | 2013-06-19 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 置換アシルアニリドおよびそれらの使用方法 |
| US8138191B2 (en) | 2007-01-11 | 2012-03-20 | Critical Outcome Technologies Inc. | Inhibitor compounds and cancer treatment methods |
| US8173647B2 (en) | 2007-02-06 | 2012-05-08 | Gordana Atallah | PI 3-kinase inhibitors and methods of their use |
| RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| DE102007036076A1 (de) * | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP5258331B2 (ja) | 2008-03-03 | 2013-08-07 | ロート製薬株式会社 | 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物 |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| TR201800962T4 (en) | 2010-03-08 | 2018-03-21 | Sloan Kettering Inst Cancer Res | CDC7 KINAZI INHIBITORS AND THEIR USAGE |
| CN106963741A (zh) * | 2010-03-29 | 2017-07-21 | Ea制药株式会社 | 含有苯基丙氨酸衍生物的医药制剂 |
| US8402515B2 (en) | 2010-05-06 | 2013-03-19 | Jonathan Weizman | Apparatus and method for establishing a peer-to-peer communication session with a client device |
| US20110287018A1 (en) | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of Treating Interstitial Cystitis |
| US8709419B2 (en) * | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| GEP201606545B (en) | 2010-11-19 | 2016-09-26 | Ecole Polytech | 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10201700698WA (en) | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2903644A4 (en) | 2012-10-05 | 2016-03-09 | Cerulean Pharma Inc | TREATMENT OF CANCER |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| JP6855243B2 (ja) * | 2014-01-24 | 2021-04-07 | エイアイ・セラピューティクス・インコーポレーテッド | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| RU2739992C2 (ru) | 2014-11-07 | 2020-12-30 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Композиции апилимода и способы их применения в лечении колоректального рака |
| HUE044557T2 (hu) | 2014-11-07 | 2019-11-28 | Ai Therapeutics Inc | Apilimod, veserák kezelésében történõ alkalmazásra |
| KR101761573B1 (ko) | 2014-12-29 | 2017-07-26 | 주식회사 인트론바이오테크놀로지 | 신규한 장출혈성 대장균 박테리오파지 Ｅｓｃ-ＣＨＰ-1 및 이의 장출혈성 대장균 증식 억제 용도 |
| WO2016126707A1 (en) | 2015-02-03 | 2016-08-11 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| US20180078561A1 (en) | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| US12030896B2 (en) | 2018-07-05 | 2024-07-09 | Mayo Foundation For Medical Education And Research | PIKfyve inhibitors |
| US20210077500A1 (en) | 2019-09-12 | 2021-03-18 | Al Therapeutics, Inc. | Pikfyve inhibitors for cancer therapy |
-
2015
- 2015-11-06 HU HUE15795318 patent/HUE044557T2/hu unknown
- 2015-11-06 PT PT15795318T patent/PT3215158T/pt unknown
- 2015-11-06 CA CA2966359A patent/CA2966359A1/en not_active Abandoned
- 2015-11-06 US US15/524,844 patent/US10206910B2/en active Active
- 2015-11-06 EP EP19171060.7A patent/EP3581184B1/en not_active Not-in-force
- 2015-11-06 MX MX2017006015A patent/MX377593B/es active IP Right Grant
- 2015-11-06 WO PCT/US2015/059512 patent/WO2016073877A1/en not_active Ceased
- 2015-11-06 EP EP15795318.3A patent/EP3215158B1/en not_active Not-in-force
- 2015-11-06 CN CN201580072608.8A patent/CN107249638B/zh not_active Expired - Fee Related
- 2015-11-06 JP JP2017543329A patent/JP6705828B2/ja not_active Expired - Fee Related
- 2015-11-06 RU RU2017119065A patent/RU2727802C2/ru active
- 2015-11-06 AU AU2015342869A patent/AU2015342869A1/en not_active Abandoned
- 2015-11-06 PL PL15795318T patent/PL3215158T3/pl unknown
- 2015-11-06 ES ES15795318T patent/ES2741399T3/es active Active
- 2015-11-06 BR BR112017008799A patent/BR112017008799A2/pt not_active Application Discontinuation
- 2015-11-06 KR KR1020177015388A patent/KR20170098812A/ko not_active Ceased
-
2017
- 2017-04-24 IL IL251905A patent/IL251905B/en active IP Right Grant
-
2018
- 2018-12-19 US US16/226,175 patent/US20190201385A1/en not_active Abandoned
-
2019
- 2019-11-26 US US16/695,814 patent/US11166944B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535601A5 (enExample) | ||
| RU2017119065A (ru) | Апилимод для применения в лечении рака почек | |
| WO2021053667A3 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
| JP2018525358A5 (enExample) | ||
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| HRP20200696T1 (hr) | Terapija u kombinaciji s inhibitorom topoizomeraze | |
| RU2017119066A (ru) | Композии апилимода и способы их применения в лечении колоректального рака | |
| JP2017535600A5 (enExample) | ||
| JP2017533963A5 (enExample) | ||
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| JP2017528475A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| JP2018516911A5 (enExample) | ||
| MX348817B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| Minguet et al. | Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives | |
| MX372942B (es) | Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[(3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer. | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| MY150993A (en) | Pyrimidine substituted purine derivatives | |
| RU2015139901A (ru) | Комбинированная терапия с использованием антител против клаудина 18.2 для лечения рака | |
| JP2017517520A5 (enExample) | ||
| JP2018508593A5 (enExample) | ||
| WO2008116053A3 (en) | Fap-activated chemotherapeutic compounds, and methods of use thereof | |
| MY202377A (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) |